The FDA has an ongoing Class II recall covering multi-dose sterile vials of compounded semaglutide from Apollo Care, LLC, across several strengths, posted on 19 August 2026. The reason given is particulate matter identified as nylon or polyamide and a silk or proteinaceous-type material. Class II is the FDA's middle category: use may cause temporary or medically reversible harm, with a remote probability of serious consequences.
This is an enforcement action against one compounder's product quality. It is not a safety finding about semaglutide, and it does not touch branded semaglutide pens, which are manufactured on a different footing entirely. The clinical relevance is to patients obtaining semaglutide as an unbranded multi-dose vial rather than a licensed pen — a route that has grown wherever the branded product is expensive or short.
For Indian practice the direct read-across is limited: the action names a US firm and this record carries no CDSCO position. What it does support is the general point to make with a patient who has sourced vials outside the licensed supply chain — that sterility and particulate control are exactly what the licensed route is buying, and that a vial from an unverifiable source cannot be assumed to be the drug at the stated strength.
- Ask patients on semaglutide whether they are using a licensed pen or a vial, and where it came from
- Recorded strengths in this recall span 2.5 mg to 20 mg vials from a single firm
- Class II here means a quality defect, not a newly identified drug risk
- Report any injection-site or systemic reaction in a patient using compounded product
- This record carries no Indian regulatory position; do not imply CDSCO has acted
Why it matters
It shifts the question from whether the drug is safe to whether this particular supply chain is.
Don't overread it
A recall for particulate contamination is a manufacturing-quality action against one firm, not a safety signal about semaglutide.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free